PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23349014-7	2013	Treatment with low-dose aspirin to mice homozygous for the TH-MYCN transgene significantly reduced the tumor burden (P < 0.01), the presence of tumor-associated cells of the innate immune system (P < 0.01), as well as the intratumoral expression of transforming growth factor-beta, thromboxane A2 (P < 0.05) and prostaglandin D2 (P < 0.01).	Aspirin	24-31	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	62-66	
23349014-8	2013	In conclusion, tumor-associated inflammation appears as a potential therapeutic target in NB and low-dose aspirin reduces tumor burden in the TH-MYCN transgenic mouse model of NB, hence warranting further studies on aspirin in high-risk NB.	Aspirin	106-113	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	145-149	
24073359-2	2013	The continuous administration of low-dose aspirin to TH-MYCN mice (a model of pediatric neuroblastoma) delays tumor outgrowth and decreases tumor-promoting inflammation by inhibiting regulatory cells of the innate immune system as well as immunosuppressive mediators such as transforming growth factor beta (TGFbeta) and thromboxane A2.	Aspirin	42-49	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	56-60